抗結核治療市場－全球產業規模、佔有率、趨勢、機會、預測：依疾病類型、診斷與治療、最終用戶、地區和競爭格局分類，2021-2031年

全球抗結核藥物市場預計將從 2025 年的 14.1121 億美元大幅成長至 2031 年的 19.9504 億美元，複合年成長率達到 5.94%。

這些治療藥物是用來對抗結核分枝桿菌感染疾病的重要藥物。市場擴張的根本驅動力是結核病發病率的上升，尤其是在疾病負擔沉重的地區，以及對抗耐多藥菌株的先進治療方案的迫切需求。此外，旨在改善全球診斷和治療可及性的強力的政府舉措和國際財政支持也推動了這一需求。世界衛生組織（世衛組織）發布的《2024年全球結核病報告》強調了疫情的嚴峻性，報告指出，2023年約有1080萬人感染結核病，並強調了持續迫切需要有效的治療方案。

市場成長的主要障礙是抗藥性日益嚴重，這降低了傳統的第一線抗生素的療效。抗藥性細菌的增加迫使醫護人員採用二線療法，而二線療法通常成本更高、毒性更大、療程更長。這些特徵往往導致患者依從性降低，並給公共衛生基礎設施帶來沉重的經濟負擔，最終阻礙現有治療方法的廣泛應用。

市場促進因素

多重抗藥性結核病 (MDR-TB) 和廣譜抗藥性結核病 (XDR-TB) 的顯著蔓延是推動市場擴張的主要因素，這促使人們需要使用標準一線治療方案以外的先進藥物。當異煙肼和利福平無效時，醫療系統會引入二線藥物和創新聯合治療，例如 BPaLs（貝達喹啉、普瑞托馬尼和Linezolid），以加速患者康復。根據世界衛生組織 (WHO) 發布的《2024 年全球結核病報告》（2024 年 10 月），2023 年約有 40 萬人患有多重抗藥性結核病或利福平抗藥性結核病。這種迫切需求尤其刺激了商業性以金額為準，這些藥物可以縮短療程並減輕傳統藥物的嚴重副作用，從而重新定義了針對抗藥性菌株的公司的商機。

政府和非政府組織投入的資金不斷增加，正在加速新型抗結核藥物和疫苗的臨床研發。這些資金的流入降低了製藥公司的財務風險，並加強了針對複雜感染疾病類型的有前景治療方法的研發管線。根據「遏制結核病夥伴關係」和「治療行動小組」發布的《2024年結核病研究資金趨勢報告》（2024年12月），2023年全球結核病研發資金達12億美元。這些投資對於擴大生產和分銷能力以滿足全球需求至關重要。世界衛生組織（世衛組織）在2024年的報告中強調了治療的廣泛需求，報告顯示，2023年全球新增結核病確診病例820萬例，是自全球監測開始以來的最高數字。

市場挑戰

抗菌素抗藥性（AMR）的蔓延是全球抗結核藥物市場擴張的一大障礙。隨著結核分枝桿菌菌株對第一線標準抗生素的抗藥性日益增強，醫護人員被迫轉向二線治療。這些替代療法的採購成本顯著高於傳統治療方法，且毒性較大。因此，這種日益加重的經濟負擔給公共衛生預算帶來了巨大壓力，尤其是在結核病高發地區，限制了政府計畫廣泛採購和分發這些基本藥物的能力。這種經濟壓力，加上影響患者依從性的副作用，直接限制了先進療法的市場覆蓋範圍和銷售量。

最新統計數據顯示，對抗藥性特異性治療方法的迫切需求與其實際應用之間存在顯著差距。世界衛生組織（世衛組織）在2025年報告中指出，到2024年，僅約有五分之二的多重抗藥性結核病患者接受了必要的治療。這項統計數據凸顯了市場面臨的一個主要限制因素：儘管存在有效的二線療法，但抗藥性細菌治療的複雜性和資源需求使得這些產品無法惠及大多數需要的患者，從而阻礙了市場成長潛力。

市場趨勢

BPaL 和 BPaLM 治療方案的廣泛應用正在迅速改變全球治療標準，使治療模式從長期注射療法轉向更高效的 6 個月全口服療法。這項重大的營運轉變使各國醫療衛生系統能夠集中供應以貝達喹啉、普瑞托馬尼和Linezolid為核心的治療藥物，從而顯著簡化供應鏈管理，並因給藥方式的簡化而提高治療完成率。這種快速的推廣應用正在重新定義市場需求，國際採購速度就是明證。根據結核病聯盟發布的 2024 年年度報告（2025 年 1 月），2024 年近 100 個國家訂購了超過 10 萬個療程的 BPaL/M 方案，這是該領域現代史上最快的治療方案推廣速度。

同時，專為兒童設計的可分散製劑的研發也在穩步推進，由此形成了一個獨特的市場區隔領域，專注於精準且便於兒童服用的給藥方式。製藥公司正逐步從壓碎成人片劑轉向開發水溶性製劑，這些製劑更易於兒童吞嚥，並確保準確的生物利用度。這種對創新製劑的關注旨在解決兒童患者在治療依從性和安全性方面面臨的重大挑戰。例如，結核病聯盟在2025年11月的新聞稿中公佈了IMPAACT 2034試驗的中期數據，該數據顯示，單次服用一種新型兒童可分散普瑞托馬尼製劑，其在兒童體內的藥代動力學暴露量與成人相當，這充分體現了這些密集研發工作的成效。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗結核藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 疾病類型（活動性結核病、潛伏性結核病、其他）
  • 診斷與治療（診斷（血液檢查、影像檢查、痰液檢查等）、治療（第一線藥物、第二線藥物等）、其他）
  • 依最終使用者（醫院、專科診所、居家醫療等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美抗結核藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲抗結核藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗結核藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲抗結核治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲抗結核藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球抗結核治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AstraZeneca Plc.
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global anti-tuberculosis therapeutics market is projected to expand significantly, from USD 1411.21 million in 2025 to USD 1995.04 million by 2031, achieving a compound annual growth rate of 5.94%. These therapeutics are essential pharmacological interventions designed to combat infections caused by Mycobacterium tuberculosis. This market's expansion is fundamentally propelled by the rising incidence of tuberculosis, particularly in areas with a high disease burden, alongside the urgent need for advanced treatment protocols to combat multi-drug resistant strains. Furthermore, strong government initiatives and international financial support aimed at improving global diagnosis and treatment accessibility are bolstering this demand. The World Health Organization's Global Tuberculosis Report 2024 highlighted the gravity of this situation, reporting that approximately 10.8 million people contracted tuberculosis in 2023, emphasizing the continuous and pressing demand for efficacious therapeutic solutions.

A primary obstacle to the market's growth is the increasing spread of antimicrobial resistance, which diminishes the effectiveness of conventional first-line antibiotics. The rise of these resistant bacterial strains compels healthcare professionals to employ second-line therapies, which typically involve higher expenses, greater toxicity, and longer treatment periods. Such characteristics often result in decreased patient compliance and impose considerable financial stress on public health infrastructures, consequently hindering the widespread adoption of existing therapeutic alternatives.

Market Driver

The significant prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis is a key driver for market expansion, demanding the use of sophisticated pharmacological agents beyond standard first-line treatments. When isoniazid and rifampicin prove ineffective, healthcare systems are prompted to acquire second-line therapeutics and innovative combinations, such as BPaL (bedaquiline, pretomanid, and linezolid), to enhance patient recovery. The World Health Organization's 'Global Tuberculosis Report 2024' (October 2024) indicated that approximately 400,000 individuals developed MDR or rifampicin-resistant tuberculosis in 2023. This critical need specifically stimulates the commercial focus on high-value, patent-protected drugs that can reduce treatment times and lessen the severe toxicities associated with older drug categories, thereby redefining revenue opportunities for companies targeting resistant strains.

Growing financial investments from both governmental and non-governmental organizations are accelerating the clinical progress of new anti-tubercular drugs and vaccines. This capital inflow diminishes the financial risks for pharmaceutical companies, nurturing a stronger pipeline of potential therapies aimed at complex infection types. The '2024 Report on TB Research Funding Trends' (December 2024) by the Stop TB Partnership and Treatment Action Group revealed that global funding for tuberculosis research and development reached US$1.2 billion in 2023. Such investments are vital for expanding manufacturing and distribution capacities to satisfy worldwide demand. Highlighting the extensive therapeutic requirement, the World Health Organization reported in 2024 that 8.2 million people were newly diagnosed with tuberculosis in 2023, marking the highest figure recorded since global monitoring began.

Market Challenge

The rising prevalence of antimicrobial resistance (AMR) poses a significant impediment to the expansion of the global anti-tuberculosis therapeutics market. As Mycobacterium tuberculosis strains increasingly resist standard first-line antibiotics, healthcare providers must turn to second-line pharmacological treatments. These alternative therapies come with substantially higher acquisition costs and more pronounced toxicity profiles than conventional treatments. As a result, this heightened financial burden severely strains public health budgets, especially in regions heavily affected by tuberculosis, restricting government programs' capacity to procure and distribute these vital medications broadly. This economic pressure, coupled with side effects that deter patient adherence, directly limits the wider commercial uptake and volume of advanced therapeutic agents.

A notable gap exists between the urgent demand for resistance-specific therapies and their actual implementation, as evidenced by recent figures. The World Health Organization reported in 2025 that only approximately two out of five individuals diagnosed with multidrug-resistant tuberculosis received the required treatment in 2024. This statistic highlights a major market constraint: despite the existence of effective second-line therapeutics, the complexities and resource demands involved in managing resistant strains prevent these products from reaching a substantial portion of the patient population needing them, thus hindering the market's potential for growth.

Market Trends

The widespread integration of BPaL and BPaLM treatment protocols is swiftly transforming the global standard of care, moving away from extended injectable regimens towards more efficient, six-month, all-oral courses. This significant operational shift enables national health systems to centralize their therapeutic supplies around bedaquiline, pretomanid, and linezolid, thereby considerably simplifying supply chain management and boosting treatment completion rates due to easier administration. The rapid pace of this implementation is redefining market demand, as demonstrated by the speed of international purchases. According to the '2024 Annual Report' by TB Alliance (January 2025), over 100,000 courses of the BPaL/M regimen were ordered across nearly 100 countries in 2024, marking the quickest therapeutic deployment in the modern history of the sector.

Concurrently, the creation of pediatric-specific dispersible drug formulations is fostering a distinct market segment dedicated to precise, child-friendly dosing. Manufacturers are progressively shifting from using fragmented adult tablets to developing pleasant, water-soluble options that guarantee accurate bioavailability for children. This emphasis on innovative formulations addresses crucial deficiencies in therapeutic adherence and safety for younger patients. Illustrating the effectiveness of these focused development efforts, interim data from the 'IMPAACT 2034' study, as reported by TB Alliance in a November 2025 press release, showed that a single dose of a novel pediatric dispersible pretomanid formulation produced pharmacokinetic exposures in children similar to those observed in adults.

Key Market Players

• AstraZeneca Plc.
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

Report Scope

In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Tuberculosis Therapeutics Market, By Disease Type

• Active TB
• Latent TB
• Others

Anti-Tuberculosis Therapeutics Market, By Diagnosis and Treatment

• Diagnosis
• Treatment
• others

Anti-Tuberculosis Therapeutics Market, By End User

• Hospitals
• Specialty Clinics
• Homecare
• others

Anti-Tuberculosis Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Tuberculosis Therapeutics Market.

Available Customizations:

Global Anti-Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Tuberculosis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Active TB, Latent TB, Others)
  • 5.2.2. By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others)
  • 5.2.3. By End User (Hospitals, Specialty Clinics, Homecare, others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Anti-Tuberculosis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Diagnosis and Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Tuberculosis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Diagnosis and Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Anti-Tuberculosis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Diagnosis and Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Anti-Tuberculosis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Diagnosis and Treatment
      • 6.3.3.2.3. By End User

7. Europe Anti-Tuberculosis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Diagnosis and Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Tuberculosis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Diagnosis and Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. France Anti-Tuberculosis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Diagnosis and Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Anti-Tuberculosis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Diagnosis and Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Anti-Tuberculosis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Diagnosis and Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Anti-Tuberculosis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Diagnosis and Treatment
      • 7.3.5.2.3. By End User

8. Asia Pacific Anti-Tuberculosis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Diagnosis and Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti-Tuberculosis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Diagnosis and Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. India Anti-Tuberculosis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Diagnosis and Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Anti-Tuberculosis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Diagnosis and Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Anti-Tuberculosis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Diagnosis and Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Anti-Tuberculosis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Diagnosis and Treatment
      • 8.3.5.2.3. By End User

9. Middle East & Africa Anti-Tuberculosis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Diagnosis and Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti-Tuberculosis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Diagnosis and Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Anti-Tuberculosis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Diagnosis and Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Anti-Tuberculosis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Diagnosis and Treatment
      • 9.3.3.2.3. By End User

10. South America Anti-Tuberculosis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Diagnosis and Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti-Tuberculosis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Diagnosis and Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Anti-Tuberculosis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Diagnosis and Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Anti-Tuberculosis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Diagnosis and Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti-Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca Plc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Private Limited
• 15.3. Eli Lilly and Company
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Mylan N.V.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Sanofi SA
• 15.8. Novartis AG
• 15.9. Sun Pharmaceutical Industries Ltd.
• 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer